• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

R&D status November 2015: DNDi Chagas disease programme

27 Nov 2015

The parasite that causes Chagas disease is transmitted by the ‘kissing bug’ and also by blood transfusion, organ transplantation, and congenitally. The disease is endemic in 21 countries in Latin America, where 70 million people are at risk.

An estimated 6 million people are infected in the region, and patient numbers are growing in non-endemic, high-income countries as well. Though currently available treatments (benznidazole and nifurtimox) show good efficacy, they still present drawbacks, including long treatment periods and side-effects. Today, it is estimated that less than 1% of those affected are treated.

DNDi’s current Chagas disease portfolio includes:


Research
Research

 One project in the research phase:

  • Chagas H2L (hit-to-lead): The project evaluates hits identified from screening and begins the process of optimizing new chemical series. If promising activity can be demonstrated in in vivo models of Chagas disease then the series will be advanced into full lead optimization programmes. This process of hit-to-lead optimization is ongoing with multiple series from several pharmaceutical companies.

Translation
Translation

Three projects are in the translation phase:

  • New Benznidazole Regimens/Combinations: From 2011 to 2013, DNDi and partners conducted a proof–of-concept study assessing three different regimens of fosravuconazole, a new drug candidate from the azole-compound class, on the one hand, and benznidazole, on the other hand, in a double-blind placebo controlled trial. This study prospectively confirmed the efficacy of benznidazole in chronic indeterminate Chagas disease but failed to show sustained efficacy for any regimen of fosravuconazole. To optimize benznidazole regimens in combination with fosravuconazole, a drug-drug interaction (DDI) study was conducted to demonstrate the safety of administering both drugs together. The study was undertaken in Buenos Aires, Argentina. Twenty-eight healthy human volunteers were recruited and the trial concluded with no major clinically relevant safety or tolerability issues identified. Following this DDI study, DNDi is undertaking preparatory activities for a proof-of-concept study that will assess simultaneously selected benznidazole new doses and durations in monotherapy and benznidazole/fosravuconazole combination regimens. The study will take place in Argentina and Bolivia and will include approximately 200 patients.
  • Fexinidazole: A Phase II proof-of-concept study of the New Chemical Entity (NCE) fexinidazole started in 2014 in Cochabamba and Tarija, Bolivia. A total of 180 patients were selected for study participation and 47 were included. The study was interrupted due to safety and tolerability issues.
  • Biomarkers: Pre-clinical studies are ongoing to identify and validate potential markers of therapeutic response in Chagas disease patients to support clinical development.

Implementation
Implementation

 Implementation and access to treatments:

Together with the Global Chagas Coalition and other key stakeholders, DNDi is actively supporting endemic countries to develop policies and mechanisms to scale up diagnosis and treatment of Chagas disease patients with existing therapies. Five pilot regions have been identified to implement operational studies and assessments of new models of intervention in partnership with National Control Programmes.

 

For more information on the partners and donors involved in DNDi’s Chagas disease programme, please click on each hyperlink that will refer you to each project.

 


 

From its Chagas disease-specific portfolio, DNDi aims to develop:

  • A new benznidazole monotherapy regimen for chronic Chagas disease patients
  • A new benznidazole and fosravuconazole combination treatment regimen for chronic Chagas disease patients
Chagas disease

Read, watch, share

Loading...
Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License